[Form 4] Zomedica Corp. Insider Trading Activity

Rhea-AI Filing Summary

Zomedica Corp. (ZOMDF) reported an insider equity award for a company director. The filing shows the grant of a stock appreciation right covering 1,823,107 shares of common stock on 11/17/2025. The right has a conversion or exercise price of $0.10 per share, becomes exercisable on 11/16/2026, and expires on 11/16/2035. Following this transaction, the director beneficially owns 1,823,107 derivative securities, held in direct ownership.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nichols Pamela

(Last) (First) (Middle)

1101 TECHNOLOGY DRIVE, STE 100

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zomedica Corp. [ ZOMDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Appreciation Right	$0.1	11/17/2025		A		1,823,107		11/16/2026	11/16/2035	Common	1,823,107	$0	1,823,107	D

Explanation of Responses:

	/s/ Pamela Nichols	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Zomedica (ZOMDF) report in this Form 4?

The filing reports that a Zomedica director received a stock appreciation right covering 1,823,107 shares of common stock in a transaction dated 11/17/2025.

How many stock appreciation rights were granted to the Zomedica director?

The director was granted a stock appreciation right over 1,823,107 derivative securities, with the same number of underlying shares of Zomedica common stock.

What is the exercise price and term of the Zomedica stock appreciation right?

The stock appreciation right has a conversion or exercise price of $0.10 per share, becomes exercisable on 11/16/2026, and expires on 11/16/2035.

What is the reporting person’s relationship to Zomedica (ZOMDF)?

The reporting person is identified as a director of Zomedica Corp., with the Form 4 indicating the relationship box for director is checked.

How many derivative securities does the Zomedica director own after this transaction?

After the reported transaction, the director beneficially owns 1,823,107 derivative securities, held with direct (D) ownership.

Is this Form 4 filed by a single reporting person for Zomedica?

Yes. The filing indicates it is a Form filed by One Reporting Person, not a joint filing with multiple insiders.